ReviewDialogues in clinical neuroscience2010
Psychiatric pharmacogenomic testing in clinical practice.
Review in Dialogues in clinical neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02411123 (Prospective Randomized Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Randomized Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the value for money of precision medicine: a systematic literature review and meta-analysis.Frontiers in public health · 2023Pooled it
- Sertraline-Induced Mood and Behavioral Activation in Two Adults With Prader-Willi Syndrome.Case reports in psychiatry · 2025Article
- Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy.Clinical pharmacology and therapeutics · 2025Review
- Candidate genetic variants and antidepressant-related fall risk in middle-aged and older adults.PloS one · 2022Article
- Article
- Literature Review Concerning the Challenges of Implementing Pharmacogenetics in Primary Care Practice.Cureus · 2020Review
- Pharmacodynamic Gene Testing in Prader-Willi Syndrome.Frontiers in genetics · 2020Article
- Pharmacokinetics of antidepressants in patients undergoing hemodialysis: a narrative literature review.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2019Review
- Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings.Neuropsychiatric disease and treatment · 2018Article
- Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.The EPMA journal · 2017Review
- CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic.Journal of community hospital internal medicine perspectives · 2017Article
- Pharmacogenomic testing: aiding in the management of psychotropic therapy for adolescents with autism spectrum disorders.Pharmacogenomics and personalized medicine · 2017Article
- New developments in the management of narcolepsy.Nature and science of sleep · 2017Review
- Toward a Global Roadmap for Precision Medicine in Psychiatry: Challenges and Opportunities.Omics : a journal of integrative biology · 2016Review
- Psychiatric Symptoms and Psychosocial Problems in Patients with Breast Cancer.The journal of breast health · 2016Review
- Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.International journal of clinical pharmacy · 2016Article
- Pharmacogenomics: A focus on antidepressants and atypical antipsychotics.The mental health clinician · 2016Article
- Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies.Molecular neuropsychiatry · 2015Article
- A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders.The primary care companion for CNS disorders · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical adoption of psychiatric pharmacogenomic testing has taken place rapidly over the past 7 years. Initially, drug-metabolizing enzyme genes, such as the cytochrome P450 2D6 gene (CYP2D6), were identified. Genotyping the highly variable cytochrome P450 2D6 gene now provides clinicians with the opportunity to identify both poor metabolizers and ultrarapid metabolizers of 2D6 substrate medications. Subsequently, genes influencing the pharmacodynamic response of medications have been made available for clinical practice. Among the earliest "target genes" was the serotonin transporter gene (SLC6A4) which has variants that have been shown to influence the clinical response of patients of European ancestry when they are treated with selective serotonin reuptake inhibitors. Genotyping of some of the serotonin receptor genes is also available to guide clinical practice. The quantification of the clinical utility of pharmacogenomic testing is evolving, and ethical considerations for testing have been established. Given the increasingly clear cost-effectiveness of genotyping, it has recently been predicted that pharmacogenomic testing will routinely be ordered to guide the selection and dosing of psychotropic medications.
Indexed as
Identifiers
20373668PMC3181940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.